In Defense of Phosphodiesterase 5 Inhibitors—Reply-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

In Defense of Phosphodiesterase 5 Inhibitors—Reply

Published:2022-09-01 Issue:9 Volume:140 Page:908
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Sodhi Mohit¹²,Mikelberg Frederick S.¹,Etminan Mahyar¹³

Affiliation:

1. Collaboration for Epidemiology of Ocular Diseases, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

2. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

3. Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2794497/jamaophthalmology_sodhi_2022_lr_220007_1663178052.08316.pdf

Reference4 articles.

1. Risk of ocular adverse events associated with use of phosphodiesterase 5 inhibitors in men in the US.;Etminan;JAMA Ophthalmol,2022

2. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.;Campbell;J Sex Med,2015

3. Food and Drug Administration adverse event reports of retinal vascular occlusions associated with phosphodiesterase type 5 inhibitor use.;Li;J Neuroophthalmol,2016

4. Viagra-associated serous macular detachment.;Quiram;Graefes Arch Clin Exp Ophthalmol,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP